Barely Significant
← all excerpts

Nonpeghylated liposomal doxorubicin combination regimen (R-COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity.

Hematol Oncol · 2020 · PMC7689940 · PMID 32542788

Europe PMCDOI
1
hedged sentence
0.0100
closest p · 0.2× alpha
0.0100
boldest claim

The sentences

at the limit of significanceP = .01actually significant
Complete remission rate was superior at the limit of significance ( P = .01) for patients who would have been able to use standard doxorubicin (76%) vs patients who would not have used doxorubicin (69%).

also in 326 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.